Transdel Pharmaceuticals, Inc. (TDLP)

[colorofmoney]

TDLP News..Transdel Pharmaceuticals Reports Excellent Results of Initial Testing on
Anti-Cellulite Product Conducted by JH Direct

LA JOLLA, Calif., Sept 09, 2010 /PRNewswire via COMTEX/ -- Transdel
Pharmaceuticals, Inc. (TDLP) ("Transdel") reported today that JH Direct has
completed their initial product testing of Transdel's anti-cellulite formulation
in 24 subjects, which consisted of observing the before and after results of
applying the product over a 16 week period. The excellent results observed during
this test have led JH Direct to initiate plans for a final test in approximately
25 subjects to be conducted by a third-party skin research center that will
conduct a similar test to the initial test as well as obtain additional
measurements over a 12 week period. JH Direct is planning a commercial launch of
the product for the fourth quarter of 2010 or in early 2011 subject to successful
completion of this final test.

Under the terms of its exclusive worldwide licensing agreement, JH Direct will
pay Transdel initial royalty advances and a continuing licensing royalty on the
worldwide sales of the anti-cellulite product. The product will be initially
launched through a direct response television campaign created and managed by JH
Direct, followed by a planned expansion into traditional channels of
distribution, such as retail and wholesale channels.

"We are pleased with JH Direct's product development progress and
commercialization plans for our anti-cellulite product; given their significant
experience and past success with direct response television campaigns we are
confident they will maximize the potential of our product," stated John Lomoro,
Acting Chief Executive Officer and Chief Financial Officer. "The eventual launch
of this product will be a significant milestone for Transdel."

"We are very pleased with the results that the participants experienced from our
initial testing and are excited to be moving into the final testing phase for the
anti-cellulite product," stated Johann Verheem, JH Direct's Chief Executive
Officer. "We believe there is a large market opportunity for an anti-cellulite
product that works as well as this product has proven in our initial testing and
we are looking forward to introducing this product to the market."

About Transdel Pharmaceuticals, Inc.

Transdel Pharmaceuticals, Inc. (TDLP) is a specialty pharmaceutical company
developing non-invasive, topically delivered products. The Company's
innovative-patented Transdel(TM) cream formulation technology is designed to
facilitate the effective penetration of a variety of products through the tough
skin barrier. Ketotransdel(R), the Company's lead pain product, has completed a
Phase 3 clinical trial and utilizes the Transdel(TM) technology to deliver the
active drug, ketoprofen, a non-steroidal anti-inflammatory drug through the skin
directly into the underlying tissues where the drug exerts its well-known
anti-inflammatory and analgesic effects. The Company intends to leverage its
Transdel(TM) platform technology to expand and create a portfolio of topical
products for a variety of indications. The Company is actively pursuing
partnerships with companies to expand its product portfolio for pharmaceutical
and cosmetic/cosmeceutical products. For more information, please visit
http://www.transdelpharma.com.

About JH Direct, LLC

JH Direct, LLC is a fully integrated Direct Response Television Company focusing
on developing sustainable brands launched through direct response television
campaigns as part of a multi-channel distribution approach. The JH Direct senior
management team has created and managed some of the most successful Direct
Response Television brands in the cosmeceutical, beauty and fitness categories
since the mid nineties.

JH Direct is funded by JH Partners, a San Francisco-based private equity firm
focused on building sustainable, long-term equity value in consumer and
marketing-driven growth companies. http://www.jhpartners.com

Safe Harbor Statement

The Company cautions you that the statements included in this press release that
are not a description of historical facts are forward-looking statements. These
include statements regarding: the Company's interpretation of the results of the
initial testing of its anti-cellulite product; the results of the final tests of
its anti-cellulite product and JH Direct's plans to commercially launch the
anti-cellulite product. Actual results may differ materially from those set forth
in this press release due to the risks and uncertainties inherent in the
Company's business, including, without limitation: the outcome of the final tests
on the Company's anti-cellulite product may not be favorable, the timing of JH
Direct's commercial launch of the anti-cellulite product may be delayed, JH
Direct's efforts to commercially launch the anti-cellulite product may not be
successful, the Company may receive limited licensing proceeds, and the Company
may be unable to secure sufficient funding to complete its product development
plans. More detailed information about the Company and the risk factors that may
affect the realization of forward-looking statements is set forth in the
Company's filings with the Securities and Exchange Commission, including its
Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q filed with the
SEC. Such documents may be read free of charge on the SEC's web site at
http://www.sec.gov. You are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date hereof. All
forward-looking statements are qualified in their entirety by this cautionary
statement and the Company undertakes no obligation to revise or update this press
release to reflect events or circumstances after the date hereof. This caution is
made under the safe harbor provisions of Section 21E of the Private Securities
Litigation Reform Act of 1995.

SOURCE Transdel Pharmaceuticals, Inc.

Copyright (C) 2010 PR Newswire. All rights reserved